logo-loader

Volte face: Johnson & Johnson re-enters acquisition talks with Swiss biotech firm Actelion

Published: 08:35 22 Dec 2016 EST

Drugs
J&J said yesterday that it had entered into “exclusive negotiations” to acquire the Swiss drugmaker, indicating that other potential suitors had left the process

In a surprising a change of heart, US healthcare giant Johnson & Johnson (NYSE:JNJ) has said it has re-entered acquisition talks with Swiss biotech firm Actelion Ltd.

J&J abruptly bowed out of the bid process for Actelion last week after the Swiss firm said that it was “engaged in discussions with another party”.

Actelion gave no details about who the third party was, but press reports at the time suggested it was French firm Sanofi SA.

Yesterday, however, J&J said that it had entered into “exclusive negotiations” to acquire the Swiss drugmaker, indicating that other potential suitors had left the process.

J&J, the world’s largest healthcare company, and Actelion said in brief, separate statements that while takeover discussions had been rekindled there was “no assurance any transaction will result.”

Actelion, Europe’s biggest biotech company with a market value of $22.5bn, could change hands for as much as $30bn, according to commentators.

The group specialises in treatments for a rare disorder known as pulmonary arterial hypertension.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 19 minutes ago